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The standard treatment for neovascular age-related macular degeneration (nAMD)
consists of intravitreal anti-vascular endothelial growth factors (VEGF). However, for
some patients, even maximal anti-VEGF treatment does not entirely suppress
exudative activity. The goal of this study was to identify molecular biomarkers in nAMD
with incomplete response to anti-VEGF treatment. Aqueous humor (AH) samples were
collected from three groups of patients: 17 patients with nAMD responding incompletely to
anti-VEGF (18 eyes), 17 patients affected by nAMD with normal treatment response (21
eyes), and 16 control patients without any retinopathy (16 eyes). Proteomic and multiplex
analyses were performed on these samples. Proteomic analyses showed that nAMD
patients with incomplete anti-VEGF response displayed an increased inflammatory
response, complement activation, cytolysis, protein-lipid complex, and vasculature
development pathways. Multiplex analyses revealed a significant increase of soluble
vascular cell adhesion molecule-1 (sVCAM-1) [p  0.001], interleukin-6 (IL-6) [p 
0.009], bioactive interleukin-12 (IL-12p40) [p  0.03], plasminogen activator inhibitor
type 1 (PAI-1) [p  0.004], and hepatocyte growth factor (HGF) [p  0.004] levels in
incomplete responders in comparison to normal responders. Interestingly, the same
biomarkers showed a high intercorrelation with r2 values between 0.58 and 0.94. In
addition, we confirmed by AlphaLISA the increase of sVCAM-1 [p < 0.0001] and IL-6 [p 
0.043] in the incomplete responder group. Incomplete responders in nAMD are associated
with activated angiogenic and inflammatory pathways. The residual exudative activity of
nAMD despite maximal anti-VEGF treatment may be related to both angiogenic and
inflammatory responses requiring specific adjuvant therapy. Data are available via
ProteomeXchange with identifier PXD02247
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INTRODUCTION
Age-related macular degeneration (AMD) is a multifactorial
pathology involving a large number of molecular elements,
such as growth factors, inflammatory molecules, proteins
implicated in the complement system, fluid regulators, radicals
and anti-oxidant factors, visual cycle products, and others
(Lambert et al., 2016). Currently, treatment is available for the
neovascular form of AMD (nAMD), consisting of intravitreal
injections of anti-vascular endothelial growth factors anti-
vascular endothelial growth factors (anti-VEGF). VEGF plays
a key role in the pathogenesis of neovascularization and
associated exudation (Spilsbury et al., 2000). Repeated
injections of anti-VEGF are needed to suppress VEGF activity,
prohibit further neovascular growth, and suppress exudation.
Similar visual improvements have been achieved with
ranibizumab (Brown et al., 2006; Rosenfeld et al., 2006),
aflibercept (Heier et al., 2012), and bevacizumab (Martin et al.,
2011).
The need for retreatment is variable, and injection frequency
can be adapted to the individual’s requirements, which are guided
mainly by signs of exudative activity. However, some patients
with nAMD never achieve the normal response of complete fluid
resolution, despite receiving anti-VEGF treatment every month
(Fogli et al., 2018). These patients are often referred to as having
refractory nAMD, showing pathologic intraretinal or subretinal
fluid on optical coherence tomography (OCT) despite monthly
treatment. The reasons for this incomplete response are unclear
(Yang et al., 2016). However, because of the incomplete response
to anti-VEGF, it is hypothesized that other molecular factors
associated with exudative activity may be involved.
This study aimed to evaluate the molecular markers in the
aqueous humor (AH) associated with nAMD, particularly in
participants with incomplete response to anti-VEGF, and to
correlate these markers with the treatment response to anti-
VEGF treatment.
MATERIALS AND METHODS
This prospective study was performed at the Jules-Gonin Eye
Hospital Medical Retina Unit and the basic science laboratory of
the same institution, which are grouped within the Foundation
Asile des Aveugles in Lausanne, Switzerland. The study protocol
was approved by the local ethics committee (CER-VD, protocol
ID 2017-02175). It adhered to all national legal requirements and
the tenets of the Declaration of Helsinki. All participants
provided written informed consent.
Samples Selection
The study used AH from three groups of participants: patients
affected by nAMD with incomplete response to anti-VEGF
treatment (group R); patients affected by nAMD with
complete fluid resolution on monthly or less frequent anti-
VEGF treatment (group N); and control patients without any
retinopathy (group C). The study protocol estimated that 20
participants in each group would allow for meaningful
conclusions. A sample volume of 0.1 ml of AH was expected
to be available for both proteomics and multiplex analysis.
To be eligible for group R, intraretinal and/or subretinal fluid
had to be present on spectral-domain OCT (SD-OCT) at each
monthly examination for at least 6 months, despite monthly
intravitreal injections of anti-VEGF (ranibizumab or
aflibercept). Anti-VEGF treatment had to be initiated and
conducted without interruption for at least 12 months. An
observe-and-plan regimen was used (Mantel et al., 2014).
Following informed consent, between 30 and 100 µl of AH
was collected, under topical anesthesia via paracentesis using a
26-gauge needle, immediately before a scheduled intravitreal
injection of anti-VEGF. After collection, the AH samples were
placed immediately in a −20°C freezer and, after 0–10 days,
transferred to our institution’s biobank for storage at −80°C.
Samples used in the study had been stored for up to 1.5 years.
Patients undergoing cataract surgery and giving informed
consent for scientific use of biological waste materials were
recruited prospectively and retrospectively (biobank) for
groups N and C. AH was collected via the first paracentesis in
the beginning of the cataract procedure. The following inclusion
criteria applied: participants in Group N had nAMD on anti-
VEGF treatment and complete dryness on SD-OCT (absence of
intraretinal and subretinal fluid) achieved with monthly or less
frequent retreatment or less frequently during the preceding
6 months. Group C had a normal retina and were only
affected by cataracts. Patients with drusen AMD or any other
retinopathy were excluded.
Exclusion criteria for all three groups included the following:
any confounding retinopathy; diabetes (independent of presence or
absence of diabetic retinopathy); insufficient visibility of the fundus
for retinal diagnosis; any anterior segment eye surgery in the study
eye within 3 months preceding AH collection; any posterior
segment surgery within 6 months; any preceding treatment such
as photodynamic treatment, laser, or intraocular or periocular
steroids within the 6 months preceding AH collection; and
inability to provide informed consent.
Complementary selection of AH samples from the biobank
(group N and group C) was performed by the laboratory
investigator (RR), guided by age-matched and sex-matched
criteria for the prospectively recruited study participants in
group R. No further clinical data regarding the coded data
from the biobank were available to the laboratory investigator.
However, the clinical investigator (IM) had full access to the
patient files and imaging documentation. All files corresponding
with the coded selected AH samples were validated by the clinical
investigator according to inclusion and exclusion criteria.
In addition to the attributes of the study group, the following
clinical data were included in the coded study database: age, sex,
anti-VEGF treatment agent (ranibizumab or aflibercept) during
6 months preceding AH sample collection, and the date of the last
injection before AH sample collection.
Proteomic Analyses
Sample Preparation
Ten AH samples per group were processed in two separate
batches of five for proteomic analyses. Proteins were digested
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according to a modified version of the iST protocol (Kulak et al.,
2014). Fifteen microliters of modified iST buffer (2% sodium
deoxycholate, 20 mM DTT, 5 mM EDTA, 200 mM Tris; pH 8.6)
was added to 15 μl of AH sample and heated at 95°C for 5 min.
Next, 10 μl of 160 mM chloroacetamide (in 10 mM Tris; pH 8.6)
was added, and cysteines were alkylated for 45 min at 25°C in the
dark. After 1:1 dilution with H2O, samples were digested with
0.2 μg of trypsin/Lys-C mix (Promega, Madison, WI, United
states) and incubated at 37°C for 1 h, followed by the addition
of a second enzyme (0.1 μg trypsin/LysC) and 1 h of incubation.
To extract deoxycholate, two volumes of ethyl acetate plus 1%
trifluoroacetic acid (TFA) were added to one volume of sample;
then, the mixture was vortexed for 2 min and centrifuged for
2 min at 5,000 rpm. The bottom aqueous fraction was loaded
onto an equilibrated OASIS MCX µElution plate (Waters,
Milford, MA, United states) prefilled with SCX0 buffer (20%
MeCN, 0.5% formic acid, 0 M ammonium acetate) and
centrifuged. The columns were washed once with 200 μl
ethylacetate plus 0.5% TFA and twice with 200 μl 2% MeCN
plus 0.1% formic acid. Then, the peptide mixture was fractionated
by sequential elution with 200 μl SCX200 buffer (20% MeCN,
0.5% formic acid, 200 mM ammonium acetate), 200 μl SCX500
buffer (20% MeCN, 0.5% formic acid, 500 mM ammonium
acetate), and 200 μl basic elution buffer (80% MeCN, 19%
water, 1% NH3).
Mass Spectrometry Analyses
Tryptic peptide fractions, prepared as described above, were
dried, and resuspended in 0.05% trifluoroacetic acid and 2%
(v/v) acetonitrile for mass spectrometry (MS) analyses. Tryptic
peptide solutions were injected using an Ultimate RSLC 3000
nano high-performance liquid chromatography (HPLC) system
(Dionex, Sunnyvale, CA, United states) interfaced with an
Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific,
Bremen, Germany). Peptides were loaded onto a trapping
microcolumn Acclaim PepMap100 C18 (20 mm × 100 μm
inner diameter [ID], 5 μm particles, 100 Å; Thermo Scientific)
before separation on a reverse-phase custom packed nanocolumn
(75 μm ID × 40 cm, 1.8 μm particles; Reprosil Pur; Dr Maisch
GmbH, Ammerbuch, Germany). A flow rate of 0.25 μl/min was
used with a gradient of 4%–76% acetonitrile in 0.1% formic acid
(total time: 65 min). Full survey scans were performed at a
resolution of 120,000, and a top speed precursor selection
strategy (Hebert et al., 2013) was applied to maximize the
acquisition of peptide tandem mass spectrometry (MS/MS)
spectra with a maximum cycle time of 0.6 s. The HCD
fragmentation mode at a normalized collision energy of 32%
and a precursor isolation window of 1.6 m/z were used; MS/MS
spectra were acquired in the ion trap. Peptides selected for MS/MS
were excluded from further fragmentation for 60 s.
Data Analysis
Tandem MS data were processed using MaxQuant software
(version 1.6.3.4) (Cox and Mann, 2008), incorporating the
Andromeda search engine (Cox et al., 2011). The UniProt
human reference proteome database for January 2019 was
used (73,950 sequences) and supplemented with sequences of
common contaminants. Trypsin (cleavage at K and R) was used
as the enzyme parameter, allowing two missed cleavages.
Carbamidomethylation of cysteine was specified as a fixed
modification. N-terminal acetylation of protein and oxidation
of methionine were specified as variable modifications. All
identifications were filtered at a 1% false discovery rate (FDR)
at both the peptide and protein levels with default MaxQuant
parameters. For protein quantitation, either the iBAQ
(Schwanhäusser et al., 2011) or the LFQ label-free values (Cox
et al., 2014) were used. MaxQuant data were further processed
with Perseus software (Tyanova et al., 2016) for filtering, log2
transformation, normalization of values, statistical analyses, and
Gene Ontology (GO) annotations.
Multiplex Analysis
A multiplex analysis was performed using Luminex xMAP
technology (ProcartaPlex; Thermo Fisher Scientific, Waltham,
MA, United states), which is a bead-based immunoassay in
microplate format. This system allows simultaneous detection
of many cytokines, chemokines, growth factors, and other
protein targets from humans in very small fluid volumes.
Each target molecule has its own standard curve, allowing a
specific quantification whose sensitivity and limit of detection
changes according to the metabolite. The target proteins for our
study were identified according to previous publications
suggesting a role within AMD (de Oliveira Dias et al., 2011;
Jonas et al., 2012; Nassar et al., 2013; Knickelbein et al., 2015; Liu
et al., 2016; Sato et al., 2018). This composed our test plate
ProcartaPlex 1. We first tested three volumes of AH (5, 10, and
20 μl) from two control patients to assess the detection limit and
the linearity of response for each analyte (Supplementary
Figure S1A). In addition, it allowed for defining the test
volume needed for each analyte. In the next step, we tested
ten AH samples per group for those analytes with a confirmed
linear response (Supplementary Figure S1B: ProcartaPlex 1). A
second round of analysis was performed with a newly composed
test plate (Supplementary Figure S1C: ProcartaPlex 2), adding
some new analytes to the confirmed linear response analytes and
using those samples with sufficient remaining fluid. To detect all
23 analytes according to the manufacturer’s protocol, 10 µl of
AH (in duplicate) were used.
AlphaLISA Assays
Homogenous no-wash immunoassays (AlphaLISA; PerkinElmer,
Waltham, MA, United states) were used to confirm the most
promising results of the multiplex analysis (human VEGF-A:
AL201; human VCAM-1: AL338; human IL-6: AL3025). We
aimed to perform the AlphaLISA for up to 10 samples, but this
was dependent on the residual AH volume available after
performing the previous steps. We used 2–5 μl (in triplicate) of
AH to perform the assay. The AlphaLISA assay contained
acceptor beads coated with an anti-analyte antibody,
streptavidin-coated donor beads, a biotinylated anti-analyte
antibody, a lyophilizate analyte (for the standard curve), and
an assay buffer (10×). After incubation with all components,
quantification of the signal was performed using an EnVision
multimode plate reader (PerkinElmer).
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Clinical Phenotypes
The clinical phenotype of nAMD in eyes included into groupsN and
R were determined based on SD-OCT, infrared images, and dye
angiography (fluorescein and indocyanine green). An experienced
retinal specialist (IM) determined the type of neovascular
membrane, the presence of reticular pseudodrusen, the presence
of complete/incomplete retinal pigment epithelium and outer retinal
atrophy (iRORA and cRORA), the presence of major fibrotic
changes, central retinal thickness, and subfoveal choroidal
thickness, and the type of exudative fluid of the recurrences
(presence of intraretinal fluid, presence of subretinal fluid).
Bio-Informatic Analyses
Statistics were performed using protein quantitation iBAQ values in
the R statistical programming environment (version 3.6.1; https://
www.r-project.org/). For analysis of the proteomics results, linear
models (R function lm) adjusted for batches were used to identify
differentially expressed proteins (p < 0.1) to compare group N and
group R and to compare groups C/N and group R. For these,
overrepresentation tests were performed using the Bioconductor
(http://www.Bioconductor.org) package ClusterProfiler (Yu et al.,
2012). The functions “enrichGO” and [OrgDb  org. Hs.e.g., db,
keyType  “ENTREZID,” ont  “ALL,” pAdjustMethod  “BH,”
pvalueCutoff  0.1, qvalueCutoff  0.1, readable  T] were used as
the parameters to test whether genes mapped on selected proteins
were significantly overrepresented in the given GO terms.
Gene Set Enrichment Analysis (GSEA) software (version 4.0.2;
http://software.broadinstitute.org/gsea) was used along with the
MSigDB annotation c5 (version 7.0; GO ontology); both of which
were provided by the Broad Institute. The minimum size of the GO
term was set to 15, and the maximum size was set to 500. One
thousand permutations were performed to assess the empirical FDR.
The first result of the GSEA was the enrichment score (ES), which
reflects the degree to which a gene set is overrepresented at the top or
bottom of a ranked list of genes. GSEA calculates the ES by walking
down the ranked list of genes and increasing a running-sum statistic
when a gene is in the gene set and decreasing it when it is not. The
normalized enrichment score accounts for differences in the gene set
size and in correlations between gene sets and the expression dataset;
it is the primary statistic for examining gene set enrichment results.
For analysis of the multiplex results, the continuous
concentration results were compared between groups using an
ANOVA test with Holm–Sidak’s correction for the three
comparisons per analyte. For correction of multiple molecules
being tested with multiplex analysis, a false discovery rate control
was applied (Benjamini and Hochberg, 1995).
The relevant molecular biomarkers were analyzed for their
association with the phenotypic features: A correlation analysis




The clinical characteristics of the groups are summarized in
Table 1. The nAMD groups R and N were similar in terms of
age and gender distribution. The neovascular phenotype
distribution was balanced, including a high proportion of type
1 neovascularization in both groups. The reticular pseudodrusen
and presence of fibrosis were equally distributed, and the mean
subfoveal choroidal thickness was similar. However, cRORA and
iRORA, as well as intraretinal fluid being implicated in the
exudative manifestations were more frequent in group N,
whilst subretinal fluid and thicker central retinal thickness was
more frequently found in group R.
The mean treatment duration was long in both groups, but
even more so for group R. In parallel, the number of injections
received preciously was more elevated in group R. The
medication used during the months before inclusion into the
study was similarly distributed between aflibercept and
ranibizumab in the groups R and N. Treatment switches had
been performed between anti-VEGF agents more frequently in
group R. The visual benefit from treatment initiation was good in
both groups, more so for group N after cataract surgery.
Proteomics Analysis
Anti-Vascular Endothelial Growth Factors-A
Quantitation
The VEGF-A concentrations were found to be increased in both
nAMD groups (groups R and N) (Figure 1A, left). Within the
nAMD groups, this increase was independent of the drug type
used and the time since the last injection (Figure 1A, right). The
expected general increase in VEGF-A served as validation of the
proteomics approach for AH. Additionally, the N-terminal parts
of the VEGF receptor-1 (VEGFR-1/FLT-1) and VEGF receptor-2
(VEGFR-2/FLK-1) were also found in higher concentrations in
both nAMD groups (Figure 1B, left). These components are part
of the aflibercept molecules, and we consider this result to be a
direct effect of aflibercept injections, as they were discovered only
in Aflibercept-treated patients (Figure 1B, right). No other
sequences of VEGFR-1 and VEGFR-2 proteins, except the
ones present in aflibercept, were detected by the proteomics
analyses. All patients treated with this drug showed increased
VEGFR-1 and VEGFR-2 up to 2 months after the last injection,
with a decrease after 3 months of aflibercept treatment; however,
no detection of this compound was observed in ranibizumab-
treated patients or in the control group (Figure 1B, right).
Gene Ontology Enrichment
Graphical heatmap representation of proteomics results using ten
AH per group (Supplementary Figure S2). The GSEA of
proteomics data comparing group R to groups N and C
detected an increase in several pathways, including the acute
inflammatory response, protein activation cascade, complement
activation, and proteins involved in coagulation (Figure 2A). The
concentration measurements for each group showed no
differences in expression or trends of low expression of
specific proteins in group N when compared to group C.
However, some proteins were clearly increased in group R
(Figure 2B), and this increase was statistically significant for
complement C5, complement C3, complement factor B (CFB),
complement factor D (CFD), complement factor H (CFH),
apolipoprotein A1 (APOA1), apolipoprotein 2 (APOA2),
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endoplasmic reticulum membrane protein complex (EMC1),
coagulation factor 12 (F12), coagulation factor 2 (F2),
intercellular adhesion molecule 2 (ICAM2), and hepatocyte
growth factor activator (HGFAC). A GSEA based on the rank
lists from the linear model analysis showed that several additional
proteins involved in cytolysis, the protein activation cascade, the
lipid complex, and regulation of vasculature development were
increased in group R (Figure 3). Whole file with GO analyses are
provided in Supplementary Data Sheet S1.
Multiplex Analysis
Within the multiplex analysis, the linearity response of the
selection of 30 analytes was evaluated within the control
group. The study revealed 15 analytes with a linear and
reproducible response, six analytes that were partially detected
with no linearity, and nine analytes that were not detected in 10 μl
of AH (Supplementary Figure S1A). We modified our panel by
removing undetected analytes and adding new ones
(Supplementary Figure S1B); this allowed for the detection of
8 additional analytes with a reliable response. Table 2 shows the
results obtained for 23 reliable analytes for all three groups of
patients, the number of AH samples tested for each group, and
the p-values obtained according to the analysis of variance
(ANOVA). The numbers of test results per analyte varied, due
to total available AH volume was often smaller than the expected
0.1 ml, some volume was used for proteomics, and some tests
failed. The numbers of successfully performed test per analyte are
given in Table 2 (between brackets after each analyte).
First, the multiplex results were analyzed to confirm the results
obtained by the proteomic analyses. A significant increase in
VEGF-A, VEGFR-1, and VEGFR-2 was observed in both group R
and group N (Table 2) without a significant difference between
these two groups. The VEGFR components were detected in
aflibercept-treated patients only (Supplementary Figure S3A).
VEGF-A levels were lower in patients treated with
ranibizumab than with aflibercept when using multiplex
analysis (Figure 4A), but they were both undetectable in
AlphaLISA (Figure 4B). In contrast, VEGF-A was detected in
control participants (Figure 4B). Additional testing of control
AH after the addition of ranibizumab or aflibercept showed
apparent interference with the detection of VEGF-A, thereby
reducing its measurement significantly (Supplementary Figures
S3B, C).
Several molecules, including soluble vascular cell adhesion
molecule-1 (sVCAM-1), hepatocyte growth factor (HGF),
plasminogen activator inhibitor type 1 (PAI-1), interleukin-12
subunit beta (IL-12p40), and interleukin-6 (IL-6), were
significantly increased in group R compared to group C and
group N (Table 2; Figure 5). The increase of these molecules
was observed in both ranibizumab- and aflibercept-treated eyes,
and the difference was non-significant between differentially treated
patients (Supplementary Figure S4A). To confirm this, we
performed an AlphaLISA for sVCAM-1 and observed a
significant increase in both ranibizumab- and aflibercept-treated
patients of group R in comparison to groups C and N (p < 0.0001).
We also comparedmultiplex andAlphaLISA assays for the detection
of sVCAM-1 and observed a correlation coefficient (r2  0.924)
suggesting that both assays are suitable and comparable
(Supplementary Figure S5A). We also tested IL-6 levels using
AlphaLISA, and we confirmed the increasing level of cytokines in
group R in comparison to groups C and N (p  0.043)
(Supplementary Figure S5B). Figure 6 shows the correlation
TABLE 1 | Demographic, phenotypic and treatment characteristics of each group based on the type of molecular analysis.
rAMD (R) nAMD (N) Control (C)
N patients 17 17 16
Mean age (SD) 81.6 (±6.5) 81.6 (±5.9) 70.44 ± 2.47
Females (%) 13 (76.5%) 13 (76.5%) 8/8
N eyes 18 19 16
Right eyes/left eyes 14/4 7/13 10/6
Neovascularization type: 1/2/3 15/2/1 16/3/1 —
Presence of reticular pseudodrusen (%) 5 (28%) 7 (35%) —
Presence of fibrosis (%) 3 (17%) 4 (20%) —
Presence of cRORA 4 (22%) 10 (50%) —
Presence of iRORA 6 (33%) 14 (70%) —
Recurrences including IRF (%) 9 (50%) 17 (85%) —
Recurrences including SRF (%) 12 (67%) 8 (40%) —
Mean CRT in micrometers (SD) 323 (±83) 286 (±76) —
Mean subfoveal choroidal thickness in micrometers (SD) 150 (±121) 166 (±64) —
Treatment duration in months ± SD 69.7 ± 35.1 55.4 ± 36.2 —
Number of injections received ± SD 59.6 ± 29.9 36.4 ± 26.7 —
Weeks from preceding injection ± SEM 5.89 ± 0.94 3.97 ± 0.29 —
Anti-VEGF agent used (ranib./Aflib.) 8/10 8/12 —
Number of switches performed
0 3 13 —
1 9 7 —
2 6 0 —
Mean visual acuity at treatment initiation in ETDRS letters ± SD 61.7 ± 12.5 63.1 ± 16.1 —
Mean visual acuity change from baseline in ETDRS letters ± SD 7.9 ± 12.5 Before cataract surgery −9.4 ± 12.9 after cataract surgery 12.8 ± 11.8 —
cRORA, complete retinal pigment epithelium pigment and outer retinal atrophy; iRORA, incomplete retinal pigment epithelium pigment and outer retinal atrophy.
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between four of these biomarkers (sVCAM-1 vs. PAI-1: R2  0.944;
sVCAM-1 vs. HGF: R2  0.750; sVCAM-1 vs. IL-12p40: R2  0.580;
HGF vs. PAI-1: R2  0.860; HGF vs. IL-12p40: R2  0.622; IL-12p40
vs. PAI-1: R2  0.758) (Figure 6), while no correlation was observed
between these four biomarkers and IL-6 (data not shown).
Multiple testings of the false discovery rate control confirmed
the statistical significance for four out of the five discussed proteins:
the reference p values for the 23 molecules included in multiplex
testing are 0.002, 0.004, 0.007, 0.009, and 0.011 for the first, second,
third, fourth and fifth significant result, respectively. Thus, sVCAM
(p  0.001), PAI-1 (p  0.004), HGF (p  0.004), and IL-6 (p 
0.009) do fulfill the false discovery rate control but not IL-12p40
does not (p  0.031).
The Eotaxin chemokine and the matrix metalloproteinase 9
(MMP-9) showed increasing values from group C to group N to
group R. However, the difference was statistically significant only
for the comparison between groupR and group C (Figure 7A). The
results were not affected by the 2 different treatments
(Supplementary Figure S4B). Both monocyte chemoattractant
protein 1 (MCP-1) and interleukin 7 (IL-7) were significantly
increased in both group R and group N (Figure 7B). For MCP-
1, the increase was independent of the anti-VEGF drug used.
However, IL-7 appeared to increase, specifically in aflibercept-
treated patients (Supplementary Figure S4C).
Exploratory Clinical-Molecular Correlation
The relevant molecular biomarkers that were associated with
incomplete anti-VEGF response (group R: sVCAM, PAI-1, HGF,
and IL-6, IL-12p40) were finally analyzed for potential associations
with clinical characteristics. The results are summarized in Table 3.
The nAMD groups N and R were different in terms of
treatment duration and number of anti-VEGF injections
FIGURE 1 | Proteomic analyses of ten AH from each group of patient nAMD (N), rAMD (R), and controls (C). Graphic representation of VEGF-A (A), VEGFR1 (C) and
VEGFR2 (E) levels obtained in the three different study groups. *p < 0.03 and #p < 0.0001 (Left). Graphs on the right represent the quantification of VEGF-A (B),
VEGFR1 (D) and VEGFR2 (F) independently of the type of AMD but depending on the anti-VEGF treatment (aflibercept [Aflib] or ranibizumab [Ranib]) and classify
according to the time after the last injection of anti-VEGF inhibitors.
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received. However, there was no association seen between
treatment duration or number of injections and any of the five
molecular biomarkers.
Additional factors that were unbalanced between the groups,
did not show any association with the molecular biomarkers
either: presence or absence of cRORA and iRORA, intraretinal or
subretinal fluid in the recurrences, and CRT.
Out of the factors that were balanced between the groups,
there was a constant negative correlation seen with the subretinal
choroidal thickness, significant for sVCAM-1, IL-12p40, and
HGF. Occasional correlations were seen for age (with IL-
12p40 and HGF, positive correlation), VA improvement (with
IL-6, negative correlation), and the CNV type (with PAI-1, higher
values for type 2 neovascularisation). However, no association
was seen with fibrosis, reticular pseudodrusen. In addition,
VEGF-A did not show any association with any of the
investigated parameters.
Correcting each clinical parameter for false discovery rate (6
molecules tested), the results remaining significant included the
subfoveal choroidal thickness (for sVCAM-1, IL-12p40, and
HGF), and type 2 neovascularization (for PAI-1).
DISCUSSION
The present study was able to identify aqueous humor molecular
biomarkers for nAMD patients with incomplete anti-VEGF
responses in comparison to nAMD patients with optimal
responses and our control group. The double approach, which
used proteomics and a specific molecular analysis, showed the
involvement of the inflammatory response, complement cascade
activation, cytolysis, protein-lipid complex, and vasculature
development pathways. In comparison with normally
responding nAMD, the incomplete responders group showed
particularly increased signals for sVCAM-1, IL-12p40, IL-6, PAI-
1, and HGF. Additionally, we were able to identify several
biomarkers involved in both nAMD groups, including VEGF-
A, MCP-1, and IL-7. A correlation analysis with clinical
biomarkers suggested an association with thinner subfoveal
choroidal thickness (higher values of sVCAM-1, IL-12p40,
and HGF).
Testing multiple proteins, as in our multiplex analysis, is
associated with a risk of rejecting the null hypothesis due to a
chance result. However, applying a statistical control strategy
reduces the sensitivity of the analysis. In the context of precious
biological material, ethical considerations apply as well. For this
reason, exploration analyses on biological material do not
necessarily require controlling for multiple testings. In our
study, we applied the false discovery control in order to show
the solidity of the results. With this strategy, four out of the five
significant results in multiplex analysis (p < 0.05) remained
significant (sVCAM-1, IL-6, PAI-1, and HGF). The fifth
analyte (IL-12p40) was thus not significant. However, as the
discussion will show below, biological pathways naturally link
FIGURE 2 | Proteomic bio-informatic analyses of ten samples per study group. (A)Dot plot showing GO enrichment. Statistical significance of the enriched terms is
based on the p-values corrected by multiple testing (color-coded). The number of genes associated with each respective term is indicated by the dot size. (B) Boxplots
expression of genes involved in GO are highlighted in red in (A)with significance levels (*p < 0.1, **p < 0.05, and ***p < 0.01) obtained from linear models comparing N and
R and comparing C/N and R.
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this molecule to the other results, and correlation coefficients
between the molecules were high. Thus, the biological plausibility
of a true rejection of the null hypothesis for IL-12p40 increases
the likelihood that it remains a biologically significant result.
VEGF-A is considered to be at the center of all neovascular
processes, and anti-VEGF treatment is the confirmed treatment
approach. Therefore, the corresponding analyses of VEGF-A
were used in our study to confirm the overall approach. The
proteomic results confirmed the implication of VEGF-A in both
nAMD groups, without significant difference between them.
Indeed, total VEGF-A is detected by a proteomic approach
which is performed in denaturing condition (Figure 1A).
Results obtained by dosages of free VEGF-A performed in
non-denaturing condition (multiplex or AlphaLISA analyses)
are challenging to interpret because VEGF-A inhibitors
interfere within the assays. The interference is depending on
the test chosen (antibodies used for the ELISA) and the anti-
VEGF agent used for the treatment (interacting differently with
VEGF-A) (Waskull et al., 2018). The comparison of free VEGF-A
level in the patient treated either with Aflibercept or Ranibizumab
is difficult, if not impossible, because of different interactions of
the drug with VEGF-A. In keeping with this hypothesis, we found
FIGURE 3 |GSEA-based GO analysis enrichment plots of representative gene sets for several pathways. The primary result of the gene set enrichment analysis is
the enrichment score (ES, at the top of the green curve), which reflects the degree to which a gene set is overrepresented at the top or bottom of a ranked list of genes.
GSEA calculates the ES by walking down the ranked list of genes, increasing a running-sum statistic when a gene is in the gene set and decreasing it when it is not. The
magnitude of the increment depends on the correlation of the gene with the phenotype. The ES is the maximum deviation from zero encountered in walking the list.
A positive ES indicates gene set enrichment at the top of the ranked list; a negative ES indicates gene set enrichment at the bottom of the ranked list. Themiddle portion of
the plot shows where the members of the gene set appear in the ranked list of genes. The bottom part of the plot shows the values of the estimates of the linear model.
Genes included in GO pathways, normalized enrichment scores, nominal p-values (from 1,000 permutations), and FDR q-values are indicated in the table. The complete
lists of the GSEA output are provided for positive and negative enrichment. For more details, see the supplemental Excel table.
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completely different levels of VEGF-A when applying VEGFA
AlphaLISA, using different antibodies than the multiplex assay.
Actually, VEGF-A became undetectable with AlphaLISA assay
(Figure 4B). In addition, Supplementary Figures S2B, C, clearly
show that anti-VEGF-A (aflibercept or ranibizumab) disrupt the
signal, in both multiplex or AlphaLISA assays, when VEGF-A is
measured in control AH patients. Therefore, an antibody-
independent approach such as proteomics is highly valuable
for total VEGF-A quantitation (Figure 1A).
Interestingly, proteomics (Figure 1B) and multiplex analyses
(Table 3; Supplementary Figure S2) detected a VEGFR signal
attributable to aflibercept in AH up to 2 months after the last
injection; this result may support the hypothesis of the long-term
presence of aflibercept in the eye. However, its presence does not
necessarily indicate effective anti-VEGF activity as it may be
saturated.
Other pathways were of particular interest to this study
because they could potentially be responsible for residual fluid
despite anti-VEGF treatment. The inflammatory pathway is one
of the most promising candidates for explaining residual
exudation. Thus, our proteomics results revealing a strong
involvement of inflammatory, immunologic, and complement
activation pathways in group R are intriguing. In addition, the
multiplex analysis results identified several specific molecules
implicated in an inflammation process in those patients. In
previous studies, several cytokines and angiogenic factors were
measured in nAMD patients (without focusing on the response
subgroups); among them, sVCAM-1, IL-6, and IL-12p40 were
increased in AH of nAMD patients (Jonas et al., 2010; Jonas et al.,
2012). Interestingly, we detected a significant increase in
sVCAM-1, IL-6, and IL-12p40, particularly in the group with
incomplete anti-VEGF response. As part of an inflammatory
process, they could provoke exudative activity not responding to
anti-VEGF treatment. Interestingly, the pro-inflammatory
TABLE 2 | Multiplex analysis of AH from nAMD patients with normal response (N), incomplete response (R) patients, and controls (C).
Control C (n) nAMD N (n) rAMD R (n) p values
C vs. N C vs. R R vs. N
VEGFR-1 100 ± 15.58 (9) 4,569 ± 1,228 (13) 4,738 ± 1,216 (12) *0.024 *0.024 0.910
VEGFR-2 100 ± 5.85 (9) 172.1 ± 18.46 (13) 220.8 ± 28.66 (12) 0.055 *0.002 0.110
VEGF-A 100 ± 9.53 (14) 714 ± 142.8 (19) 712.4 ± 125.6 (18) **0.003 **0.003 0.992
EGF 100 ± 2.14 (10) 105 ± 3.26 (10) 110.5 ± 1.71 (10) 0.242 *0.016 0.242
Eotaxin 100 ± 12.57 (13) 165 ± 23.5 (19) 238.8 ± 41.1 (18) 0.154 *0.011 0.151
HGF 100 ± 10.03 (14) 129.4 ± 10.82 (19) 232 ± 35.43 (18) 0.388 **0.001 **0.004
IL-12p40 100 ± 7.40 (14) 155.9 ± 14.15 (19) 210 ± 20.47 (18) *0.031 #0.0001 *0.031
sVCAM-1 100 ± 8.93 (14) 122.8 ± 12.63 (19) 242.7 ± 35.69 (18) 0.511 #0.0005 **0.001
IL-6 100 ± 25.70 (6) 86.12 ± 64.25 (7) 10,546 ± 7,320 (10) *0.042 0.11 **0.009
IP-10 100 ± 16.91 (14) 235.5 ± 42.06 (19) 280.2 ± 62.2 (18) 0.107 *0.038 0.490
MCP-1 100 ± 6.46 (14) 137.8 ± 11.16 (19) 154.3 ± 11.35 (18) *0.032 **0.002 0.253
MMP-9 100 ± 18.31 (13) 233.3 ± 42.79 (19) 325.4 ± 64.23 (18) 0.144 *0.011 0.174
Adiponectin 100 ± 33.65 (4) 131.7 ± 32.36 (9) 173.2 ± 60.66 (8) 0.762 0.741 0.762
Eotaxin-3 100 ± 18.98 (5) 145.9 ± 27.1 (9) 120.3 ± 19.7 (10) 0.781 0.857 0.781
Ghrelin 100 ± 5.83 (4) 105.3 ± 5.74 (9) 103 ± 8.74 (8) 0.960 0.960 0.960
IL-3 100 ± 25.06 (5) 122.7 ± 36.17 (4) 110.5 ± 23.78 (5) 0.946 0.946 0.928
IL-7 100 ± 18.25 (8) 290.5 ± 44.59 (12) 360.1 ± 40.22 (11) **0.006 #0.0005 0.203
MIF 100 ± 17.19 (4) 138.9 ± 20.84 (9) 133.5 ± 20.95 (8) 0.619 0.619 0.848
NGAL 100 ± 19.1 (9) 120.1 ± 10.53 (13) 135.4 ± 13.54 (12) 0.451 0.187 0.451
PaI-1 100 ± 8.5 (12) 179.9 ± 18.39 (13) 425.7 ± 89.64 (13) 0.304 #0.0005 **0.005
Gro-alpha-KC 100 ± 8.27 (14) 94.71 ± 5.60 (19) 162.7 ± 42.79 (17) 0.887 0.199 0.1669
IL-1RA 100 ± 32.02 (12) 70.77 ± 14.78 (16) 149 ± 61.91 (14) 0.652 0.652 0.4121
IL-13 100 ± 0.90 (10) 96.14 ± 3.46 (10) 97.66 ± 2.16 (10) 0.608 0.749 0.749
The number of samples tested for each group of patient is mentioned between brackets after each analyte (n). Results are expressed as mean ± SEM and as % of the control (*p < 0.05,
**p < 0.005, and #p < 0.0005, using ANOVA Holm-Sidak’s multiple comparisons test per analyte). Significant values are showed in bold.
FIGURE 4 | Level of VEGF-A in AH from nAMD patients with normal
response (N), incomplete response (R), and controls (C). The VEGF-A was
assessed by multiplex (A) or AlphaLISA (B) assays, and the results expressed
are dependent on the anti-VEGF treatment (aflibercept [Aflib] or
ranibizumab [Ranib]). **p < 0.0003 and #p < 0.0001.
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cytokine IL-6 has been associated with the progression of nAMD
(Seddon et al., 2005). It has also been shown to be elevated in the
plasma of patients with dry and wet AMD (Nielsen et al., 2019)
and during the late stage of AMD, leading to geographic atrophy
(Zofia et al., 2019). The observed role of IL-6 in incomplete
responders is in accordance with the study results of Chalam and
colleagues who showed the correlation of aqueous IL-6 with
central subfield macular thickness and an increase in IL-6
cytokine in patients who respond less to bevacizumab
treatment (Chalam et al., 2014). However, another study did
not confirm a difference in good and poor responders to aqueous
IL-6 (Pongsachareonnont et al., 2018), possibly related to the
small number of included cases.
In addition to the IL-6 increase, our study revealed a
significant increase in sVCAM-1, particularly in incomplete
responders. Interestingly, this molecule is known to be directly
regulated by IL-6 (Wei et al., 2018) and to have a role in the
immune response via IL-12p40 production (Stanley et al., 2008).
Thus, it is not surprising that we found increased IL-12p40 in
group R as well, although not clearly confirmed after controlling
for multiple testing. However, it has been previously associated
with early AMD (Klein et al., 2014) and with nAMD patients
(Jonas et al., 2012). We hypothesize that an anti-inflammatory
treatment targeting either IL-6 or sVCAM-1 could be a promising
adjuvant treatment for anti-VEGF incomplete responders.
Interestingly, a recent publication has reported adjuvant
dexamethasone use to be structurally effective in cases with
incomplete anti-VEGF response (Calvo et al., 2014). However,
given the potential steroidal side effects, there is a need for well-
designed prospective studies to help identify the most promising
candidates for this approach.
In addition to inflammation, we observed a significant increase
in vasoproliferative factors, such HGF and PAI-1, in the
refractory group R as compared to the optimal response
nAMD group N. HGF is involved in blood vessel formation
via its receptor c-Met; this process is VEGF-independent (Cai
et al., 2000). Moreover, a recent study showed an increase in
many angiogenic factors, including HGF, after an intravitreal
injection of bevacizumab (Cabral et al., 2017). Similarly, our
proteomic analysis found an increase in HGF activator (HGFAC),
a molecule with the capacity to upregulate HGF (Figure 2B). In
addition to HGF, we also noted an increase in PAI-1, which has
been reported to have proangiogenic activity in choroidal
experimental neovascularization (Lambert et al., 2001).
Interestingly, HGF can upregulate PAI-1, at least in human
liver-derived HepG2 cells (Imagawa et al., 2006). Even if
aqueous PAI-1 seems to be generally unchanged in AMD
patients (Bertelmann et al., 2013), it could be upregulated in
response to anti-VEGF treatment. Our finding that both PAI-1
and HGF were mainly associated with incomplete anti-VEGF
FIGURE 5 |Multiplex analysis of AH from nAMD patients with normal response (N), incomplete response (R), and controls (C). Graphic representation of sVCAM-1,
PAI-1, HFG, IL-12p40, and IL-6. Results are expressed as mean ± SEM and as % of the control group (*p < 0.05, **p < 0.005, and #p < 0.0005).
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responses suggests that these VEGF-independent pathways are
co-responsible for residual fluid, whether this is part of a
particular phenotype of nAMD, or a secondary upregulation
in response to anti-VEGF treatment. Therefore, both HGF and
PAI-1 could be new potential targets of treatment for patients
with nAMD responding poorly to anti-VEGF.
In our results, treatment with aflibercept vs. ranibizumab
seemed to influence the molecular concentrations described
before. However, the study was not designed for this subgroup
analysis, and the numbers were too small for conclusive results. In
the light of our previous discussion regarding drug interactions
and test results, we considered using AlphaLISA for replication of
the multiplex results for sVCAM (Supplementary Figure S4). In
fact, we found similar increases in both aflibercept-treated and
ranibizumab-treated patients within group R, contrasting with
the difference seen on multiplex tests. Therefore, the role of the
anti-VEGF agent was not clear. The available material did not
allow for further investigations of this issue.
However, the issue about incomplete anti-VEGF response,
often called refractory nAMD, is complex. There are a number
of open questions to investigate, which might finally become
relevant to the interpretation of our results. First, incomplete
responders are likely to be a inhomogeneous group. Besides
inflammatory and vasoproliferative pathways, there are potential
factors such as drug tolerance, polypoidal choroidal vasculopathy,
large pigment epithelium detachments, and degenerative changes
which might play a role (Yang et al., 2016). Furthermore, the
residual fluid observed atmonthly visits might show some dynamic
changes within the first month, as the maximum response often
occurs earlier than at 1 month (Bontzos et al., 2019). Thus, besides
inhomogeneity within incomplete responders, there might be a
continuous spectrum of the degree of response. In order to
eliminate borderline cases, the study required at least 6 months
of persistent fluid for group R. Furthermore, clinical biomarkers
were investigated for their potential association with higher
molecular biomarkers. The groups R and N differed in terms of
mean duration of preceding treatment and number of anti-VEGF
injections received, the mean visual acuity change, as well as for the
distribution of intraretinal vs. subretinal fluid, central retinal
thickness, and atrophic changes. However, none of these
showed any association with the molecular biomarkers. On the
other hand, out of the balanced clinical factors, there was a strong
suggestion for thinner choroidal thickness being associated with
higher concentrations of sVCAM-1, IL-12p40, and HGF, thus
FIGURE 6 | Correlation between different AH biomarkers in group R with incomplete anti-VEGF response. Levels of 4 biomarkers were compared in AH of
incomplete responders. A linear regression (R2) was measured in all comparisons. sVCAM-1 vs. PAI-1: R2  0.944; sVCAM-1 vs. HGF: R2  0.750; sVCAM-1 vs.
IL-12p40: R2  0.508; HGF vs. PAI-1: R2  0.806; HGF vs. IL-12p40: R2  0.622; IL-12p40 vs. PAI-1: R2  0.758.
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implying both inflammatory and vasoproliferative molecules. This
contrasts with the absence of association with reticular
pseudodrusen, which are known to be associated with thinner
choroid. However, future studies should focus on the role of the
choroid, and particularly the choriocapillaris. Thinning might go
along with ischemia of the RPE, and induce more inflammatory
and vasoproliferative response.
Limitations of the present study include the relatively small
number of patients in each group and the failure to obtain reliable
measurements for a subset of targeted molecules. Furthermore,
the study was not designed to identify the influence of the anti-
VEGF agent. Therefore, any conclusions regarding these
subgroups need to be handled with care. The control group
was not completely age-matched with the both nAMD groups
and also showed a mild imbalance of sex distribution. However,
the molecules with significant differences between the groups are
not known to be age- or sex-dependent. In addition, the focus of
this study was the difference between groups N and R, and these
were both age- and sex-matched.
In conclusion, using the proteomics and multiplex analysis, we
found that patients with nAMD incompletely responding to anti-
VEGF treatment showed a significant increase in molecular markers
FIGURE 7 |Multiplex analysis of AH from nAMD patients with normal response (N), incomplete response (R), and controls (C). Graphic representation
of EOTAXIN and MMP-9 (A) and of MCP-1 and IL-7 (B) levels in the study groups. Results are expressed as mean ± SEM and as % of the control (*p < 0.05,
**p < 0.005, and #p < 0.0005).
TABLE 3 | Clinical-Molecular Association Analysis: The five relevant molecules, associated with incomplete anti-VEGF response, were explored for potential associations
with clinical parameters, in all neovascular age-related macular degeneration (nAMD) eyes included. Correlation analysis was performed for continuous variable, and
Anova test for categorical variables.
sVCAM-1 IL-12p40 IL-6 PAI-1 HGF VEGF-A
Continuous
variables
r2 p r2 p r2 p r2 p r2 p r2 p
Age 0.20 0.22 0.32 0.05 0.17 0.29 0.24 0.13 0.38 0.01 0.07 0.67
N anti-VEGF injections 0.26 0.10 0.30 0.06 0.26 0.11 0.13 0.42 0.26 0.10 0.13 0.42
N months of treatment 0.14 0.40 0.21 0.19 0.25 0.10 0.08 0.60 0.15 0.35 0.09 0.60
VA change from baseline 0.18 0.25 0.01 0.93 −0.35 0.03 0.16 0.32 0.18 0.27 −0.11 0.47
Central retinal thickness 0.19 0.24 0.29 0.07 0.04 0.80 0.26 0.12 0.18 0.26 0.04 0.82
Subfoveal choroidal thickness −0.40 0.01 −0.46 0.003 −0.27 0.10 −0.26 0.10 −0.44 0.005 −0.14 0.38
Categorical variables p p p p p p
Reticular pseudodrusen 0.38 0.69 0.36 0.56 0.86 0.58
Intraretinal fluid 0.74 0.87 0.22 0.41 0.8 0.55
Subretinal fluid 0.73 0.4 0.42 0.99 0.93 0.69
cRORA 0.83 0.7 0.36 0.36 0.7 0.51
iRORA 0.97 0.61 0.42 0.89 0.71 0.65
CNV type 0.1 0.62 0.83 0.005 0.36 0.38
Fibrosis 0.95 0.92 0.66 0.5 0.99 0.5
cRORA, complete retinal pigment epithelium pigment and outer retinal atrophy; iRORA, incomplete retinal pigment epithelium pigment and outer retinal atrophy. Significant values are showed in bold.
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in AH associated with inflammatory response and
neovascularization/vascular development pathways. In addition,
proteomic analyses also described the implication of complement
cascade activation, cytolysis, and the protein-lipid complex. The
multiplex approach highlighted specific molecules, undetectable by
the proteomics approach, that were involved in the angiogenic
process (HGF, PAI-1) and the inflammatory response (sVCAM-
1, IL-6, IL-12p40). The causal relationship with residual fluid will
have to be confirmed by further studies, with the final aim to define
new therapeutic targets to improve the outcomes of nAMD with
incomplete anti-VEGF response. The latter could include steroids as
well as more specific targeting of molecules such as found in our
study to be implicated in incomplete anti-VEGF response.
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